Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The cognitive effect of anticholinergics for patients with overactive bladder
Blayne Welk, Kathryn Richardson, Jalesh N. Panicker
Nature Reviews Urology (2021) Vol. 18, Iss. 11, pp. 686-700
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

SUFU white paper on overactive bladder anticholinergic medications and dementia risk
Jacqueline Zillioux, Blayne Welk, Anne M. Suskind, et al.
Neurourology and Urodynamics (2022) Vol. 41, Iss. 8, pp. 1928-1933
Closed Access | Times Cited: 32
Discovery of Diphenyl Ether Derivatives as Novel BKCa Channel Activators: Structure-Activity Relationship, Cryo-EM Complex Structures, and In Vivo Animal Studies
Soo Bin Park, Na Young Lee, Eun-Young Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Overactive Bladder Medications in Geriatrics—Risks and Realities
Tyler Trump, Howard B. Goldman
Clinics in Geriatric Medicine (2025)
Closed Access
European Academy of Neurology (EAN)/European Federation of Autonomic Societies (EFAS)/International Neuro‐Urology Society (INUS) Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines)
Jalesh N. Panicker, Alessandra Fanciulli, Magdalena Krbot Skorić, et al.
European Journal of Neurology (2025) Vol. 32, Iss. 4
Open Access
Pharmacotherapy of bladder dysfunction — past, present and future
Karl‐Erik Andersson
Continence Reports (2025) Vol. 14, pp. 100080-100080
Closed Access
A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin
Carolina M. Casselini, Henri K. Parson, Katie Frizzi, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Closed Access | Times Cited: 3
Overactive bladder and cognitive impairment in middle-aged women: A cross-sectional study
Jungeun Park, Yoosoo Chang, Hye Rin Choi, et al.
Maturitas (2024) Vol. 187, pp. 108042-108042
Closed Access | Times Cited: 3
Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report
Katherine L. Dengler, Rachel High, Daniela C. Moga, et al.
Urogynecology (2022) Vol. 29, Iss. 1S, pp. S1-S19
Closed Access | Times Cited: 12
The gut, vaginal, and urine microbiome in overactive bladder: a systematic review
Christina Sze, Mariel Pressler, John R. Lee, et al.
International Urogynecology Journal (2022) Vol. 33, Iss. 5, pp. 1157-1164
Closed Access | Times Cited: 11
The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review
Blayne Welk
Indian Journal of Urology (2024) Vol. 40, Iss. 2, pp. 82-87
Open Access | Times Cited: 2
Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A
Hann-Chorng Kuo
Tzu Chi Medical Journal (2024) Vol. 36, Iss. 3, pp. 260-270
Open Access | Times Cited: 2
Risk of dementia associated with the use of anticholinergic medications: a review of recent literature
Hachem Ziadeh, Stephen Rhodes, David Sheyn, et al.
Current Opinion in Urology (2024) Vol. 34, Iss. 6, pp. 444-451
Closed Access | Times Cited: 2
Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis
Sihong Shen, Jia Xue, Liao Peng, et al.
International Urology and Nephrology (2022) Vol. 54, Iss. 4, pp. 737-747
Closed Access | Times Cited: 9
Symptomatic Care in Multiple System Atrophy: State of the Art
Anna Grossauer, Victoria Sidoroff, Beatrice Heim, et al.
The Cerebellum (2022) Vol. 22, Iss. 3, pp. 433-446
Open Access | Times Cited: 9
Prescribing cascades: how to detect them, prevent them, and use them appropriately
Tobias Dreischulte, Faiza Shahid, Christiane Muth, et al.
Deutsches Ärzteblatt international (2022)
Open Access | Times Cited: 9
The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia
Blayne Welk, J. Andrew McClure
European Urology Open Science (2022) Vol. 46, pp. 22-29
Open Access | Times Cited: 9
Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options
Anirban Ganguly, Shachi Tyagi, Christopher Chermansky, et al.
Drugs & Aging (2023) Vol. 40, Iss. 3, pp. 241-261
Open Access | Times Cited: 5
Urinary dysfunction in patients with vascular cognitive impairment
Panpan Zhao, Guimei Zhang, Yanxin Shen, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 4
A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder–wet Patients over the Age of 75 Years with Mild Cognitive Impairment
Saima Rajabali, Prosper Asaana, Sahar Nazari, et al.
European Urology Focus (2024) Vol. 10, Iss. 2, pp. 325-331
Closed Access | Times Cited: 1
The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists
Blayne Welk
European Urology Focus (2022) Vol. 9, Iss. 1, pp. 168-171
Closed Access | Times Cited: 7
Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment
Tatiana V. D. Sanses, Jacqueline Zillioux, Rachel High, et al.
Urogynecology (2022) Vol. 29, Iss. 1S, pp. S20-S39
Closed Access | Times Cited: 7
Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study
Sheng‐Fu Chen, Yao‐Chi Chuang, Chung‐Cheng Wang, et al.
Journal of the Formosan Medical Association (2022) Vol. 121, Iss. 10, pp. 2101-2108
Open Access | Times Cited: 5
Lower urinary tract dysfunction in uncommon neurological diseases: A report of the neurourology promotion committee of the International Continence Society
Blayne Welk, Ryuji Sakakibara, Sanjay Sinha, et al.
Continence (2022) Vol. 1, pp. 100022-100022
Open Access | Times Cited: 5
Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study
Wang Li, Yanduo Lin, Hong Xie, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease
Udit Saraf, Amit Batla, Ryuji Sakakibara, et al.
Drugs & Aging (2023) Vol. 40, Iss. 10, pp. 909-917
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top